SEC Form 4 · accession 0000899243-18-016531
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony B Evnin
Director
Period of report
Jun 12, 2018
Accepted (ET)
Jun 14, 2018 · 8:33 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2018 | A | 11,428 | $1.75 | A | 130,013 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.75 | Jun 12, 2018 | A | 20,000 | A | — | Jun 12, 2028 | Common Stock | 20,000 | 20,000 | D |
| Stock Option (right to buy)F3 | $1.75 | Jun 12, 2018 | A | 2,000 | A | — | Jun 12, 2028 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately half of such person's $40,000 annual retainer for service as a director.
- F2The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
- F3The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Nominating and Corporate Governance Committee of the issuer's Board of Directors.